Regentis Biomaterials Secures Key Japan Patent for GelrinC Cartilage Treatment

Regentis Biomaterials (NYSE American: RGNT) has secured a pivotal patent allowance from the Japan Patent Office, covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation for GelrinC(R), a regenerative treatment for articular cartilage injuries. This milestone expands the company's global intellectual property portfolio as it advances commercialization in Europe, continues enrolling patients in its pivotal U.S. clinical trial, and evaluates entry into additional international markets. The allowed patent protects protein-polymer conjugate compositions and manufacturing methods that eliminate organic solvents, enabling stable liquid formulations. According to Regentis, this technology improves manufacturing efficiency, increases production yield, simplifies processes, and enhances scalability for commercial production. The patent also strengthens the company's position in Japan, one of the largest cartilage repair markets worldwide, where demand is expected to rise with an aging population and increasing prevalence of knee osteoarthritis.

Regentis Biomaterials Ltd is a regenerative medicine company focused on developing innovative tissue repair solutions, initially targeting orthopedic treatments. Its Gelrin platform technology uses synchronized, degradable hydrogel implants to regenerate damaged tissue, including inflamed cartilage and bone. The lead product, GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. GelrinC(R) aims to address a market of approximately 470,000 annual cartilage knee repair cases in the U.S., where no off-the-shelf treatment is currently available. This patent allowance comes as part of a broader strategy to secure intellectual property across key markets, supporting the company's growth and commercialization efforts.

For more details, the full press release is available at https://ibn.fm/w7h5A. This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.